Amgen And AstraZeneca's TEZSPIRE Meets Both Co-Primary And All Key Secondary Endpoints In Phase 3 CROSSING Trial For Eosinophilic Esophagitis

Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52

Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports Broad Potential of TEZSPIRE